This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This study was a multi-centre, randomised controlled trial in which community pharmacists undertook a single review of the medical records of a random sample of patients and recommended medication changes to the GP as appropriate. The patients were followed up for 6 and 12 months after the intervention. Randomisation was undertaken using random number tables. The follow-up rate at 12 months was 84% of those at baseline.
Analysis of effectiveness
The analysis of effectiveness was conducted on an intention to treat basis. The main health outcomes used in the analysis were:
patients with a history of myocardial infarction ordering antiplatelet drugs; diabetic patients with a history of myocardial infarction ordering ACE-inhibitors; avoidance of beta-blockers in those with chronic obstructive pulmonary disease; use of lipid-lowering drugs in those with hyperlipidaemia.
Other outcomes were: angina patients receiving home visits for cardiovascular disease (CVD); angina patients visiting an outpatient department for CVD; and angina patients visiting the GP surgery for CVD. 
Effectiveness results

Quality of life measures did not differ between the groups.
After the intervention: 7.6% (95% confidence interval, CI: 1.7 to 13.8) more patients in the intervention group were ordering antiplatelet drugs; 2.9% (95% CI: 0.7 to 5.4) more angina patients in the intervention group received fewer home visits for CVD; 3.7% (95% CI: 0 to 7.5) more angina patients in the control group made fewer visits to an outpatient department for CVD; and 1.8% (95% CI: 0.6 to 3.5) more angina patients in the control group made fewer visits to the GP surgery for CVD.
Other outcomes showed no significant changes.
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Note-based medication review by community pharmacists resulted in small improvements.
Measure of benefits used in the economic analysis
The authors did not provide a summary measure of benefits. In effect, the authors carried out a cost-consequences analysis.
Direct costs
This study reported the direct costs to the NHS. The costs included in the study were those of hospital admissions, home visits, outpatient attendance, surgery attendance, tests, prescribing and the pharmacists' time. The unit costs of NHS contacts were calculated using standard methods. Proprietary drug costs were based on the chemist and druggist price list, and generic drugs on the Scottish Drug Tariff. The costs were reported as the median (mean) cost per patient per 6-month period. The costs were not discounted. The price year was 1999.
Statistical analysis of costs
A statistical analysis of the costs was conducted. Non-parametric tests (Mann-Whitney test) were applied.
Indirect Costs
Productivity costs were not considered.
Currency
UK pounds sterling ().
Sensitivity analysis
The examination of uncertainty was restricted to a statistical analysis of the per-patient cost.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
When the pharmacist's time cost was excluded, for the scenarios of all patients, the median (mean) total cost per patient was slightly higher for the intervention group. However, the difference was not significant in the period after intervention for all patients, when the median (mean) costs of the intervention versus control groups were 106.32 (201.41) versus 98.71 (195.20) during 0 -6 months, (p=0.085), and 92.96 (174.51) versus 88.18 (153.70 ) during 6 -12 months, (p=0.091).
When the diagnostic sub-groups were considered separately, the hypertension patients (but not the angina patients) showed statistically significantly higher costs than controls just before and immediately after the intervention. For hypertension patients, the median (mean) costs of the intervention versus control groups were 61. For all patients, when the pharmacist time cost was included, the costs of the intervention group were significantly higher than controls in the 6 months after intervention.The median (mean) costs of the intervention versus control groups were 137.29 (231.48) versus 98.71 (195.20) during the 0 -6 months after intervention, (p<0.001), and 92.96 (174.51) versus 88.18 (153.70) during the 6 -12 months after intervention, (p=0.091).
